Can environmental pollutant bisphenol A increase metabolic risk in polycystic ovary syndrome?


Journal

Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 11 04 2020
revised: 04 05 2020
accepted: 05 05 2020
pubmed: 11 5 2020
medline: 14 1 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

Bisphenol A (BPA), a widespread industrial substance is recognized as endocrine disrupting chemical and therefore could be associated with polycystic ovary syndrome (PCOS) related metabolic disturbances. In this study 29 women of reproductive age with diagnosed PCOS were enrolled. BPA in urine samples was analyzed by gas chromatography-mass spectrometry. BPA was detected in urines of 48.28% participants. The waist-to-height ratio (WtHR) was statistically significant higher in PCOS BPA+ in comparison to PCOS BPA- women (p = 0.046). PCOS BPA+ women had 6.88 times (95%Cl 1.3481-35.0600, z = 2.319, p = 0.020) higher risk for waist circumference above 80 cm and 4.95 odds (95%Cl 1.0169-24.096, z = 1.981, p = 0.048) to have WtHR over 0.5 when compared to PCOS BPA-. Statistically significant positive association between BPA urine concentrations and insulin serum levels (p = 0.038) was obtained. BPA urine values were associated with elevated HOMA-IR values and reduced HDL levels with moderate significance (p = 0.079 and p = 0.061, respectively). Also, there was 3.75 times (95%Cl 0.7936-17.7203, z = 1.668, p = 0.095) higher risk for PCOS BPA+ women to have testosterone levels above reference values. The obtained results suggested that the BPA exposition in PCOS women was followed by increased metabolic risk through promotion of obesity, especially the visceral type, hyperinsulinemia, insulin resistance, dyslipidemia and elevated androgen levels.

Sections du résumé

BACKGROUND BACKGROUND
Bisphenol A (BPA), a widespread industrial substance is recognized as endocrine disrupting chemical and therefore could be associated with polycystic ovary syndrome (PCOS) related metabolic disturbances.
PATIENTS METHODS
In this study 29 women of reproductive age with diagnosed PCOS were enrolled.
METHODS METHODS
BPA in urine samples was analyzed by gas chromatography-mass spectrometry.
RESULTS RESULTS
BPA was detected in urines of 48.28% participants. The waist-to-height ratio (WtHR) was statistically significant higher in PCOS BPA+ in comparison to PCOS BPA- women (p = 0.046). PCOS BPA+ women had 6.88 times (95%Cl 1.3481-35.0600, z = 2.319, p = 0.020) higher risk for waist circumference above 80 cm and 4.95 odds (95%Cl 1.0169-24.096, z = 1.981, p = 0.048) to have WtHR over 0.5 when compared to PCOS BPA-. Statistically significant positive association between BPA urine concentrations and insulin serum levels (p = 0.038) was obtained. BPA urine values were associated with elevated HOMA-IR values and reduced HDL levels with moderate significance (p = 0.079 and p = 0.061, respectively). Also, there was 3.75 times (95%Cl 0.7936-17.7203, z = 1.668, p = 0.095) higher risk for PCOS BPA+ women to have testosterone levels above reference values.
CONCLUSION CONCLUSIONS
The obtained results suggested that the BPA exposition in PCOS women was followed by increased metabolic risk through promotion of obesity, especially the visceral type, hyperinsulinemia, insulin resistance, dyslipidemia and elevated androgen levels.

Identifiants

pubmed: 32387634
pii: S0009-8981(20)30206-0
doi: 10.1016/j.cca.2020.05.009
pii:
doi:

Substances chimiques

Benzhydryl Compounds 0
Environmental Pollutants 0
Phenols 0
bisphenol A MLT3645I99

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

257-263

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Maja Milanović (M)

University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia.

Nataša Milošević (N)

University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia. Electronic address: natasa.milosevic@mf.uns.ac.rs.

Jan Sudji (J)

University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia.

Stefan Stojanoski (S)

University of Novi Sad, Faculty of Medicine, Oncology Institute of Vojvodina, Center for Imaging Diagnostics, Sremska Kamenica, Serbia.

Milica Atanacković Krstonošić (M)

University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia.

Artur Bjelica (A)

University of Novi Sad, Faculty of Medicine, Department of Gynecology and Obstetrics, Clinics for Gynecology and Obstetrics, Clinical Center of Vojvodina, Novi Sad, Serbia.

Nataša Milić (N)

University of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, Serbia.

Milica Medić Stojanoska (M)

University of Novi Sad, Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Vojvodina, Novi Sad, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH